Coxia 60 mg tablet: Each coated tablet contains Etoricoxib INN 60 mg.
Coxia 90 mg tablet: Each coated tablet contains Etoricoxib INN 90 mg.
Coxia 120 mg tablet: Each coated tablet contains Etoricoxib INN 120 mg.
Coxia is the preparation of Etoricoxib, an NSAID that exhibits anti-inflammatory, analgesic and antipyretic activities. It is a practical potent, highly selective COX-2 inhibitor. COX-2 is primarily responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. Selective inhibition of COX-2 decreases the clinical signs and symptoms with decreased GI toxicity and without effects on platelet function.
Route of administration : Coxia should be taken in oral route.
Osteoarthritis : 30 mg once daily. Dose can be increased to 60 mg once daily.
Chronic musculoskeletal disorder, dysmenorrhea & chronic low back pain : 60 mg once daily.
Rheumatoid arthritis & ankylosing spondylitis : 90 mg once daily.
Acute gout & following dental surgery : 120 mg once daily
Hepatic impairment In patients with mild hepatic impairment (Child-Pugh score 5-6), a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic impairment (Child-Pugh score 7-9), the dose of 60 mg every other day should not be exceeded; administration of 30 mg once daily can also be considered. Coxia is contraindicated in patients with severe hepatic impairment (Child-Pugh score ≥10).
Warfarin anticoagulant effect is enhanced (monitor INR); lithium and methotrexate excretion reduced increasing toxicity; ACE inhibitors have reduced antihypertensive action.
It is contraindicated in patients with known hypersensitivity to etoricoxib or any other components of this product. It is also contraindicated in patients with active peptic ulceration or gastrointestinal (Gl) bleeding, patients with creatinine clearance <30 ml/min, patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following the administration of acetylsalicylic acid or other NSAIDs, patient having inflammatory bowel disease and congestive heart failure.
Common: Edema, fluid retention, dizziness, headache, palpitations, hypertension, gastrointestinal disorder, ecchymosis.
Overdose
In case of overdose, general supportive measures and proper monitoring should be initiated.
Category C (1st/2nd trimesters), Category D / Contraindicated in 3rd trimester. Inhibits uterine contractions and causes premature closure of fetal ductus arteriosus; contraindicated in pregnancy. Lactation: Excretion in human milk unknown; breastfeeding not recommended.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.